The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation

The results of a major international clinical trial coordinated by the Montreal Heart Institute were reported today in the New England Journal of Medicine. The Atrial Fibrillation and Congestive Heart Failure Trial (AF-CHF) was a prospective, multicentre project involving patients with heart failure and atrial fibrillation. Heart failure is an important cause of death in the population and associated atrial fibrillation (a very common heart rhythm disorder) further increases the risks. The trial was launched in 2001 and enrolled 1,376 patients at 123 hospital sites in North America, South America, Europe and Israel. The project's goal was to improve treatment with the objective of reducing mortality and morbidity linked with atrial fibrillation and heart failure. Made possible by a grant of more than $6.5 million from the Canadian Institutes of Health Research (CIHR), this study was directed by Dr. Denis Roy, a cardiologist at the Montreal Heart Institute (MHI) and Chair of the Department of Medicine at the Université de Montréal, in collaboration with Dr. Mario Talajic, also a cardiologist at the MHI, and several Canadian researchers and international experts who contributed to this large-scale research project.

Between May 2001 and June 2005, the 1,376 patients were randomly assigned to a rhythm-control strategy (where patients received electrical shocks and medication to suppress the abnormal rhythm) or a more simpler strategy of rate-control (where two common drugs, beta-blockers and digitalis, are used to prevent rapid heart rates with no specific efforts to regularize the rhythm). The primary endpoint of the study was cardiovascular mortality. Data management and analysis were performed at the Montreal Heart Institute Coordinating Center (MHICC).

The intention-to-treat analysis revealed no difference in the primary endpoint between the two groups. Cardiovascular death occurred in 182 (27%) patients in the rhythm-control group compared with 175 (25%) in the rate-control arm. Total mortality, worsening heart failure and stroke were similar between the two groups. Hospitalizations were more frequent in the rhythm-control group, many due to hospitalization for management of atrial fibrillation.

The AF-CHF trial provides important new information concerning two widely-used treatment strategies for atrial fibrillation in patients with heart failure. The routine use of a rhythm-control strategy did not reduce the rate of death in comparison with a rate-control strategy. Furthermore, there were no significant differences in other important outcomes such as worsening heart failure or stroke. The rate-control strategy eliminated the need for repeated cardioversions and reduced rates of hospitalization. In conclusion, the results of this trial suggest that rate-control, should be considered the primary approach for patients with atrial fibrillation and congestive heart failure.

"It is now clear that the rate-control strategy offers a less complex approach for the management of atrial fibrillation and could reduce rates of hospitalization" says Dr. Denis Roy, the principal investigator.

"The result of this provocative study challenges the conventional wisdom, and shows that these patients can be conservatively managed, without repeated electric shocks. This will serve as a new goal post for future care of these patients," said Dr. Peter Liu, Scientific Director of the CIHR Institute of Circulatory and Respiratory Health.

Atrial fibrillation is a cardiac rhythm disorder in which the upper chamber of the heart (the atria) beats irregularly and very rapidly. Patients may experience this in the form of palpitations, shortness of breath or chest pain. This is the most common form of sustained arrhythmia. Contrary to ventricular fibrillation (originating in the ventricles or lower chamber of the heart), atrial fibrillation is rarely fatal but does require treatment as it can lead to severe discomfort, heart failure or stroke. Atrial fibrillation affects roughly 2.2 million Americans, predominantly the elderly.

Congestive heart failure affects over 4 million Americans and the number of patients suffering from heart failure will continue to rise over the next few decades. Heart failure is a clinical syndrome where the heart is unable to pump enough blood to satisfy the organism's metabolic needs. In roughly two-thirds of cases, the dysfunction is caused by defective cardiac muscle contraction due to coronary disease and hypertension. Despite recent advances in our understanding of the physiopathology of heart failure and the development of new drugs, the prognosis remains serious. The five-year mortality rate is 50%, and heart failure is the main cause of cardiovascular hospitalizations.

Founded in 1954 by Dr. Paul David, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in prevention, ultra-specialized care, training of professionals, clinical and fundamental research, and assessment of new technologies. It is affiliated with the Université de Montréal and its clinical outcomes are among the best in the world.

The MHI Research Centre officially came into existence in 1976 and has made enormous strides since its creation. Today, there are approximately 500 employees, students and researchers at the MHI Research Centre. The MHI's outstanding feature is the balance it achieves between basic research, clinical research and clinical care. Its primary focus areas of research are vascular diseases, myocardial function and cardiac electrophysiology. MHI researchers also contribute to the advancement of knowledge and medical applications in the fields of genomics (in particular in disease gene discovery and pharmacogenomics), biomarkers and preventive cardiology. To learn more about the Institute, please visit our website at www.icm-mhi.org.

Deeply rooted in Montreal and dedicated to its international mission, the Université de Montréal is one of the top universities in the world, particularly in the French-speaking world. Founded in 1878, the Université de Montréal together with its two affiliated schools, HEC Montréal and École Polytechnique constitutes the largest centre of higher education and research in Québec and the second largest in Canada. Advancing healthcare is a top priority for the Université de Montréal, whose scientists are internationally renowned for their practical and clinical investigations. In addition, the University is Canada's sole institute of higher education to provide instruction in every discipline related to health,

The Canadian Institutes of Health Research is the Government of Canada's agency for health research. CIHR's mission is to create new scientific knowledge and to catalyze its translation into improved health, more effective health services and products, and a strengthened Canadian health-care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 11,000 health researchers and trainees across Canada.

Information:
Doris Prince
Head, Communications and Public Relations
Montreal Heart Institute
514 376-3330, Extension 3074
doris.prince@icm-mhi.org

Valérie Gonzalo
514 626-6976
gonzalo@videotron.ca